Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update [Yahoo! Finance]
Armata Pharmaceuticals, Inc. (ARMP)
Company Research
Source: Yahoo! Finance
focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2023 , and provided a corporate update. Fourth Quarter 2023 and Recent Developments: Continued to advance the Phase 2a portion of the Company's diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia with continued ability to dose escalate due to phage purity, as well as its Phase 2 Tail wind study of AP-PA02 in patients with non-cystic fibrosis bronchiectasis (NCFB). Reported that analysis of data from the SWARM- P.a. clinical trial of AP-PA02 in cystic fibrosis patients with Pseudomonas aeruginosa respiratory infections, together with blinded trends from the ongoing Tail wind NCFB study, indicate that treatment with phage alone compared to phage plus antibiotics results in a similar biologic impact. Additionally, similar
Show less
Read more
Impact Snapshot
Event Time:
ARMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARMP alerts
High impacting Armata Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARMP
News
- Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate UpdatePR Newswire
- Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva [Yahoo! Finance]Yahoo! Finance
- Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaPR Newswire
- Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit [Yahoo! Finance]Yahoo! Finance
- Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy SummitPR Newswire
ARMP
Earnings
- 11/14/23 - Miss
ARMP
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEF
- 3/22/24 - Form 8-K
- ARMP's page on the SEC website